Abstract
Background Polycystic ovary syndrome (PCOS) and hypothyroidism are the most common endocrinological disorders among women of reproductive age. Since hypothyroidism occurs more frequently in PCOS patients, it is vital to explain its clinical impact. Aim To evaluate the impact of subclinical hypothyroidism (SCH) and its treatment on the metabolic profile of patients with PCOS. Methods 190 women with PCOS phenotype A were enrolled in the case-control study. They were divided into three groups: 38 women with PCOS and subclinical hypothyroidism, 76 women with PCOS and SCH under thyroid replacement therapy, and 76 women with PCOS and normal thyroid function (control group). Serum lipids, fasting glucose, and insulin, as well as oral glucose tolerance tests were performed. Results In the analyzed parameters, there were no statistic differences between the groups in relation to thyroid function. BMI turned out to be the main factor dividing the patients in terms of serum lipids, fasting glucose, fasting insulin, and oral glucose tolerance test. TSH was associated with total cholesterol and LDL cholesterol levels, whereas BMI has a dominant impact on HDL cholesterol, triglycerides, glucose, and insulin resistance. Conclusions SCH is associated with mild lipid serum alterations in women with PCOS, but it is BMI to have a dominant impact on glucose and insulin. It seems that treatment of SCH in PCOS does not significantly alter lipid and glucose metabolism.
Highlights
Polycystic ovary syndrome (PCOS) is a disease that affects all stages of a woman’s life. e full clinical picture of ovulation disorders, hyperandrogenism, and polycystic morphology of the ovaries in ultrasound is revealed in women of reproductive age [1, 2]. e cascade of events related to the coexistence of PCOS includes intrauterine growth restriction (IUGR), low birth weight, obesity, metabolic syndrome, cardiovascular diseases, noninsulin-dependent diabetes mellitus, and endometrial cancer
In the study groups: untreated, treated, and control, statistically significant differences were found between patients with normal and higher BMI in terms of lipidogram components: high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol fractions and triglycerides (Figures 2(a)–2(c))
The treatment of subclinical hypothyroidism (SCH) accompanying PCOS does not significantly improve lipid and glucose metabolism. It seems that SCH is not able to significantly aggravate the already existing disorders of carbohydrate metabolism and affect the lipid profile of women with fullblown PCOS
Summary
Polycystic ovary syndrome (PCOS) is a disease that affects all stages of a woman’s life. e full clinical picture of ovulation disorders, hyperandrogenism, and polycystic morphology of the ovaries in ultrasound is revealed in women of reproductive age [1, 2]. e cascade of events related to the coexistence of PCOS includes intrauterine growth restriction (IUGR), low birth weight, obesity, metabolic syndrome, cardiovascular diseases, noninsulin-dependent diabetes mellitus, and endometrial cancer. Polycystic ovary syndrome (PCOS) and hypothyroidism are the most common endocrinological disorders among women of reproductive age. Aim. To evaluate the impact of subclinical hypothyroidism (SCH) and its treatment on the metabolic profile of patients with PCOS. BMI turned out to be the main factor dividing the patients in terms of serum lipids, fasting glucose, fasting insulin, and oral glucose tolerance test. SCH is associated with mild lipid serum alterations in women with PCOS, but it is BMI to have a dominant impact on glucose and insulin. It seems that treatment of SCH in PCOS does not significantly alter lipid and glucose metabolism
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
